GLP1S - semaglutide

Rows are ordered by price per mg: listed price divided by stated peptide content, excluding shipping and codes, so every vial competes on the same axis. Each row carries its own $/mg figure, so the size of the gap between vendors is visible, not just the order. Sprays follow the vials, unranked.

The best-documented testing flag goes to the vendor publishing batch-level, third-party certificates. The shipping flag goes to the fastest published delivery from a domestic warehouse. Data is re-checked on a schedule and each row carries its verification date.

Long-acting GLP-1 receptor agonist — the most-studied peptide for weight loss and metabolic health.

A 31-residue GLP-1 receptor agonist described in the peer-reviewed literature. Modified fatty-acid side chain confers extended half-life via albumin binding. For laboratory characterisation only.

GLP1-S (Semaglutide) is an FDA-approved GLP-1 receptor agonist with 94% homology to human GLP-1. A 2026 meta-analysis confirms 17.1% mean weight loss at 12 months, with tirzepatide showing superior results (-22.1%). Cardiovascular outcomes trials demonstrate significant reduction in MACE events. Ongoing research explores oral formulations and combination therapies.

In-vitro cAMP assays report full agonism at the human GLP-1 receptor. The C18 fatty-acid modification is described in the literature as the structural driver of albumin-mediated extended half-life.

In-vitro / preclinical characterisation only — no clinical or therapeutic claim is expressed or implied. Research use only.

GLP1-S is a GLP-1 receptor agonist peptide analog (94% homology to human GLP-1). GLP1-S (Semaglutide) is an FDA-approved GLP-1 receptor agonist with 94% homology to human GLP-1. A 2026 meta-analysis confirms 17.1% mean weight loss at 12 months, with tirzepatide showing superior results (-22.1%). Cardiovascular outcomes trials demonstrate significant reduction in MACE events. Ongoing research explores oral formulations and combination therapies. It has a molecular formula C187H291N45O59, mass 4113.58 Da. Common synonyms in the literature include Semaglutide, semaglutide, and Ozempic.

Investigation of GLP1-S to date is clinical-investigational, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing GLP1-S spans SUSTAIN clinical trial program: Series of Phase 3 trials establishing glp1-s's efficacy for type 2 diabetes. SUSTAIN-6 (n=3,297) demonstrated cardiovascular safety and 26% reduction in major adverse cardiovascular events. HbA1c reductions of 1.5-1.8% were consistently observed, STEP clinical trial program: Phase 3 trials for chronic weight management. STEP 1 (n=1,961) showed 14.9% mean weight loss vs 2.4% placebo over 68 weeks in adults with obesity. STEP 2-4 confirmed efficacy across different populations and treatment contexts, and SELECT cardiovascular outcomes trial: Large outcomes trial (n=17,604) in patients with established cardiovascular disease and overweight/obesity without diabetes. Demonstrated 20% reduction in major adverse cardiovascular events, leading to expanded indications. Proposed mechanisms in the literature include GLP-1 receptor binding: selectively activates GLP-1R, a G protein-coupled receptor on pancreatic beta cells and cAMP/PKA pathway: triggers adenylate cyclase activation, increasing cyclic AMP and protein kinase A activity. None of this material describes therapeutic outcomes in humans, and No vendor listed here provides dosing guidance for GLP1-S outside laboratory research.

For the full mechanistic profile, published references, and constraint notes on GLP1-S, see the GLP1-S research page. All references cited on that page are peer-reviewed primary literature.

Binding and functional-assay data for GLP1-S, from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.

Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.

Structural and in-vitro receptor-binding attributes of published incretin research compounds. Reference chemistry only — no comparative-effectiveness claim expressed or implied.